Medical experts come together to share their views in this on-demand webinar replay of an interactive online discussion:

Treatment options for HCC patients who are not eligible for or progressed on IO. Clinical considerations and when to switch.

 

  • The independent expert panel examined the outcomes of patients with hepatocellular carcinoma (HCC) who underwent first-line immunotherapy (IO) and discussed clinical considerations for switching treatment
  • They also covered treatment options for patients with HCC who are not eligible for IO in 1st line, the data supporting 2nd line treatment options, and how to achieve optimal sequencing
  • The event concluded with speakers and participants engaging in a Q&A to address pressing questions

 

Watch the replay, divided into 4 digestible videos below, download the accompanying slides, and take the accredited e-learning using the blue button below the videos.

Timon Vandamme is a Senior Consultant in digestive and neuroendocrine oncology at the Antwerp University Hospital. As a clinician-researcher, he is performing research in circulating cell-free DNA (ccfDNA) in digestive and neuroendocrine neoplasms.

 

Dr Vandamme obtained a joint PhD at the University of Antwerp, Belgium and the Erasmus MC, the Netherlands, on preclinical and translation evaluation of everolimus resistance and pancreatic NET genomics. His PhD project has led to multiple publications in peer-reviewed journals and received numerous awards, both national and international. Currently, he is holder of a Senior Clinical Investigator (FKM) grant of the Fonds Wetenschappelijk Onderzoek (FWO) at the University of Antwerp.

 

Furthermore, he is the Principal Investigator (PI) of > 10 trials at the University Hospital Antwerp, both industry-sponsored and academic trials. He is promotor of four PhD students and mentor of two additional PhD students. He has authored numerous papers outside his PhD in journals such as Clinical Cancer Research and Lancet Oncology. He has peer-reviewed for different high-impact journals and is a member of the editorial board of Endocrine-Related Cancer.

He is currently acting secretary of the Dutch Belgian Neuroendocrine Tumor Society (DBNETS) and co-opted board member of the Belgian Group of Digestive Oncology (BGDO). In addition, he is active member of the EORTC GI Tract Cancer Group and the ENETS Translational Working Group.

 

Dr Changhoon Yoo is a medical oncologist who specialises in the care of patients with gastrointestinal cancers including hepatocellular carcinoma. He is an Assistant Professor at Asan Medical Center in Seoul, South Korea. Dr Yoo obtained his medical degree at the University of Ulsan College of Medicine, Seoul, South Korea and completed post graduate training at Asan Medical Center. He has participated in multiple clinical trials and translational research for the development of novel agents for patients with hepatocellular carcinoma. His research initiatives include the integration of novel targeted and immune-based therapy into the treatment of hepatocellular carcinoma. Relevant publications Kim HD, Song GW, Park S, Jung MK, Kim MH, Kang HJ, Yoo C, Yi K, Kim KH, Eo S, Moon DB, Hong SM, Ju YS, Shin EC, Hwang S, Park SH. Association Between Expression Level of PD1 by Tumor-Infiltrating CD8+ T Cells and Features of Hepatocellular Carcinoma. Gastroenterology 2018 Aug 23; pii: S0016-5085(18)34897-2. doi: 10.1053/j.gastro.2018.08.030. [Epub ahead of print] PMID: 30145359 Yoo C, Kang J, Lim HY, Kim JH, Lee MA, Lee KH, Kim TY, Ryoo BY. Phase I Dose-Finding Study of OPB-111077, a Novel STAT3 Inhibitor, in Patients with Advanced Hepatocellular Carcinoma. Cancer Res Treat 2018 Jun 13. doi: 10.4143/crt.2018.226. [Epub ahead of print] PMID: 29898591 
Chae H, Cho H, Yoo C, Kim KP, Jeong JH, Chang HM, Kang J, Lee HC, Lim YS, Kim KM, Shim JH, Lee SS, Park DH, Song TJ, Hwang S, Song GW, Moon DB, Lee YJ, Lee JH, Ryoo BY. Prognostic implications of hepatitis B virus infection in intrahepatic cholangiocarcinoma treated with first-line gemcitabine plus cisplatin. Int J Biol Markers 2018 Jun 1:1724600818777239. doi: 10.1177/1724600818777239. [Epub ahead of print] PMID: 29874985 
Cho H, Yoo C, Kim KP, Jeong JH, Kang J, Chang HM, Lee SS, Park DH, Song TJ, Lee SK, Kim MH, Lee HC, Lim YS, Kim KM, Shim JH, Hwang S, Song GW, Moon DB, Lee JH, Lee YJ, Ryoo BY. Prognostic Implication of Inflammation-based Prognostic Scores in Patients with Intrahepatic Cholangiocarcinoma Treated with First-line Gemcitabine plus Cisplatin. Invest New Drugs 2018 Jun;36(3):496-502. doi: 10.1007/s10637-017-0548-7. Epub 2017 Dec 1. PMID: 29192354 Yoo C, Kang J, Kim D, Kim KP, Ryoo BY, Hong SM, Hwang JJ, Jeong SY, Hwang S, Kim KH, Lee YJ, Hoeflich KP, Schmidt-Kittler O, Miller S, Choi EK. Multiplexed gene expression profiling identifies the FGFR4 pathway as a novel biomarker in intrahepatic cholangiocarcinoma. Oncotarget 2017 Jun 13;8(24):38592-38601. doi: 10.18632/oncotarget.16951.

Asst. Prof. Changhoon Yoo has received financial support/sponsorship for research support, consultation, or speaker fees from the following companies:

Bayer, Eisai, MSD, Ono and Ipsen.

Programme summary
  • clock Duration 24 MIN
  • clock Language(s) flag
Take the e-learning now
Other episodes in this series
Treatment Options for HCC Patients Not Eligible for or Progressed on Immunotherapy

Treatment Options for HCC Patients Not Eligible for or Progressed on Immunotherapy

Episode 1: Reviewing the outcomes in HCC with 1st line immunotherapy

Current Episode
Treatment Options for HCC Patients Not Eligible for or Progressed on Immunotherapy

Treatment Options for HCC Patients Not Eligible for or Progressed on Immunotherapy

Episode 2: Patients with advanced HCC not eligible for IO in 1st line

Treatment Options for HCC Patients Not Eligible for or Progressed on Immunotherapy

Treatment Options for HCC Patients Not Eligible for or Progressed on Immunotherapy

Episode 3: Overview of 2nd line treatment options in advanced HCC

Share this programme
This educational programme is supported by an Independent Medical Education Grant from Bayer
Endorsement
I agree that this educational programme:

Was valuable to me

1/4
Brought to you by
HCC CONNECT

HCC CONNECT is an initiative of COR2ED, supported by Independent Medical Educational Grants from AstraZeneca, Bayer and Eisai Europe Limited.

Meet the experts

Other programmes of interest

Podcast
Oncology 
Colorectal cancer: understanding the needs of different patient populations

Exploring the impacts of age, ethnicity, socioeconomic status, and access to healthcare on patients with colorectal cancer

Experts
Prof. Tanios Bekaii-Saab, Deneen Richmond, Oncology Brothers (Moderators)
Endorsed by
COLONTOWN
  • download Downloadable
    Resources
  • clock 25 MIN
  • calendar May 2024

Educational programme supported by an Independent Medical Education grant from Bayer.
Podcast
Oncology 
Interpreting real-world evidence in later-line mCRC

Aligning real-world evidence with clinical trial data 

Experts
Prof. Tanios Bekaii-Saab, Prof. Shubham Pant
  • download Downloadable
    Resources
  • clock 27 MIN
  • calendar May 2024

Educational programme supported by an Independent Medical Education grant from Bayer.
Podcast

Episode

1

of 3

episode
Oncology 
Cáncer de próstata: Dificultades en la fase preanalítica y pruebas de biomarcadores (Spanish)

Moderado por los Oncology Brothers. Episodio 1 de una serie de podcast de video de 3 partes.

Experts
Dr Alexander Wyatt, Dr Petros Grivas, Oncology Brothers (Moderators)
Endorsed by
NASPCC AMP
  • download Downloadable
    Resources
  • clock 30 MIN
  • calendar May 2024

Educational programme supported by an Independent Medical Education grant from AstraZeneca and Amoy Diagnostics.
Podcast

Episode

3

of 3

episode
Oncology 
Câncer de Ovário: Desafios da fase pré-analítica e teste de biomarcadores (Portuguese)

Moderado pelos Oncology Brothers. Episódio 3 da série de podcasts em vídeo de 3 partes

Experts
Assoc. Prof. Martina Murphy, Assoc. Prof. Caterina Marchiò, Oncology Brothers (Moderators)
Endorsed by
AMP
  • download Downloadable
    Resources
  • clock 32 MIN
  • calendar May 2024

Educational programme supported by an Independent Medical Education grant from AstraZeneca and Amoy Diagnostics.
Podcast

Episode

3

of 3

episode
Oncology 
Cáncer de ovario: Dificultades en la fase preanalítica y pruebas de biomarcadores (Spanish)

Moderado por los Oncology Brothers. Episodio 3 de una serie de podcast de 3 partes.

Experts
Assoc. Prof. Martina Murphy, Assoc. Prof. Caterina Marchiò, Oncology Brothers (Moderators)
Endorsed by
AMP
  • download Downloadable
    Resources
  • clock 32 MIN
  • calendar May 2024

Educational programme supported by an Independent Medical Education grant from AstraZeneca and Amoy Diagnostics.
Podcast

Episode

2

of 3

episode
Oncology 
Câncer de Pulmão: Desafios da fase pré-analítica e teste de biomarcadores (Portuguese)

Moderado pelos Oncology Brothers. Episódio 2 da série de podcasts em vídeo de 3 partes

Experts
Dr Bruna Pellini, Dr Semir Vranić, Oncology Brothers (Moderators)
Endorsed by
AMP
  • download Downloadable
    Resources
  • clock 25 MIN
  • calendar May 2024

Educational programme supported by an Independent Medical Education grant from AstraZeneca and Amoy Diagnostics.